Drug design strategies for the treatment of coronavirus infection

About authors

1 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

2 Institute of Biophysics SB RAS, Federal Research Center “Krasnoyarsk Science Center SB RAS”, Krasnoyarsk, Russia

3 Pirogov Russian National Research Medical University, Moscow, Russia

Corresponding author: Alexandra Sergeevna Tsarkova
Miklukho-Maklay, 16/10, Moscow, 117997, Russia; moc.liamg@avokrastla

About paper

Funding: this work was financially supported by grant № 075-15-2021-1049 from the Ministry of Science and Higher Education of the Russian Federation.

Contributing authors: S.S. Terekhov, V.I. Shmygarev, K.V. Purtov — literature analysis; I.V. Yampolsky, I.V. Smirnov — literature analysis, general project management; A.S. Tsarkova — literature analysis, data processing, project management, article writing.

Received: 2022-12-05 Accepted: 2022-12-19 Published online: 2022-12-28

The increasing size and density of the human population is leading to an increasing risk of infectious diseases that threaten to spread yet another pandemics. The widespread use of vaccination has reduced morbidity and mortality associated with viral infections and in some cases eradicated the virus from the population entirely. Regrettably, some virus species retain the ability to mutate rapidly and thus evade the vaccine-induced immune response. New antiviral drugs are therefore needed for the treatment and prevention of viral diseases. Modern research into the structures and properties of viral proteases, which are of key importance in the life cycle of viruses, makes it possible, in our opinion, to turn these enzymes into promising targets for the development of effective viral disease control methods.

Keywords: antiviral drugs, viral proteases, protease inhibitors, prodrug design